Nick Waddell is the Founding Editor at Cantech Letter. He focuses on finance, trading, and business economics, with a particular emphasis on capital markets, economic policy, and investment strategies. His insights and analyses have been featured in various outlets, showcasing his expertise in the financial markets and the broader economy.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Nick Waddell's coverage predominantly focuses on investment analysis and cites data extensively. He covers topics such as stock market movements, analyst recommendations, Canadian stocks, and inflation.
Given this focus, Nick would likely be most receptive to pitches that offer unique insights into the Canadian stock market or provide detailed analytics supporting sales and marketing strategies within the realm of investments. Additionally, he may be interested in expert opinions related to specific companies or sectors within Canada.
Since his geographic focus is national (Canada), relevant information should pertain to Canadian markets or have implications for investors within the country.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Beacon Securities analyst Donangelo Volpe has maintained a “Speculative Buy” rating and $2.00 target on Sparq Systems
Haywood Capital Markets analyst Gianluca Tucci has initiated coverage of Xtract One Technologies with a “Buy” rating and $1.00 target
“The debasement trade is moving back into favour with renewed strength in precious metals and crypto,” Habib said
Ventum Capital Markets analyst Daniel Lavoie reiterated his “Buy” rating and $44.00 target on 5N Plus in his Aug. 27 update
RBC said current U.S. tariffs affect about 5% of Canadian exports to the United States and about 0.4% of Canadian GDP and jobs
Research Capital analyst Andre Uddin has maintained his “Buy” rating and $2.90 target on Covalon
RBC economist Abbey Xu said the Q2 report shows Canada entered the latest period of trade disruption from a stronger starting point
“Given the regional uncertainty and the lack of visibility on revenue and margins, we have moved the stock to Under Review until we get better clarity…”
Research Capital analyst Andre Uddin has maintained his “Speculative Buy” rating and $0.70 target on Theralase
Paradigm Capital analyst Daniel Rosenberg has reiterated his “Buy” rating and $0.10 target on Snipp
